Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 1,057 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,057 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $43,928.92. Following the completion of the transaction, the senior vice president now owns 121,013 shares of the company’s stock, valued at $5,029,300.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Paula Green also recently made the following trade(s):

• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total value of $13,941.18.

Twist Bioscience Trading Up 5.3 %

Shares of Twist Bioscience stock opened at $45.42 on Thursday. The business’s fifty day simple moving average is $43.64 and its 200 day simple moving average is $45.43. The firm has a market capitalization of $2.66 billion, a P/E ratio of -11.89 and a beta of 1.78. Twist Bioscience Co. has a 12 month low of $15.85 and a 12 month high of $60.90.

Institutional Trading of Twist Bioscience

Hedge funds have recently made changes to their positions in the company. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the period. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience in the 2nd quarter worth about $43,000. Blue Trust Inc. boosted its holdings in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Twist Bioscience in the 2nd quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares during the last quarter.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of analyst reports. Barclays lowered their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird raised their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Evercore ISI raised their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.